A Study of Adagrasib Plus Pembrolizumab Plus Chemotherapy vs. Placebo Plus Pembrolizumab Plus Chemotherapy in Participants With Previously Untreated Non-squamous Non-small Cell Lung Cancer With KRAS G12C Mutation (KRYSTAL-4)

• Status: RECRUITING
• Trial end date: 2032-04-30

Summary

This is a trial to evaluate the efficacy, safety, and tolerability of adagrasib plus pembrolizumab plus platinum-doublet chemotherapy versus placebo plus pembrolizumab plus platinum-doublet chemotherapy in participants with previously untreated, locally advanced or metastatic NSCLC with KRAS G12C mutation

• Phase: PHASE3

Details

• Lead Sponsor: Mirati Therapeutics Inc.
• Treatments: adagrasib; Carboplatin; Cisplatin; pembrolizumab; Pemetrexed